Blood and Bone Marrow Cancer Treatment Market By Indication (Multiple Myeloma, Leukemia, Lymphoma and Others), By Therapy (Chemotherapy, Immunotherapy, Stem Cell Transplant and Radiotherapy) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Industry Outlook

The blood and bone marrow cancer treatment market is set to reach from US$ 38.8 Bn in 2018 to US$ 74.9 Bn by 2027 at a compound annual growth rate (CAGR) of 7.7% during the forecast period from 2019 to 2027. As per the research findings brought forward by Janssen Pharmaceutica N.V. approximately 900,000 people throughout the globe are diagnosed with blood cancer annually, it holds a share of 7% of all types of known cancer. 

Market Synopsis

Get a sample copy for more information

"Increasing prescription of immunosuppressive drugs for treating chronic infections and genetic mutation together are responsible for the growing incidence of lymphoma worldwide"

Lymphoma is leading the indication segment for blood and bone marrow cancer treatment market. Hodgkin lymphoma and Non-Hodgkin lymphoma are the 2 types prevalent worldwide. The important parameters responsible for its growing incidence throughout the globe are increasing prescription of immunosuppressant drugs for treating chronic infections and genetic mutations. Leukemia occurs when the DNA of immature white blood cells gets damaged due to exposure to ionizing radiation, hazardous chemicals, smoking, etc. The prevalence rate varies according to ethnicity with high occurrence in men in comparison to women population worldwide.

Get a sample copy for more information

"Strong product pipeline will ensure rampant market growth for immunotherapy during the forecast period"

Chemotherapy is dominating the therapy segment for blood and bone marrow cancer treatment market. The primary factor responsible for its increasing prescription worldwide is the availability of its generic version at affordable cost, drastically reducing the healthcare burden on ailing patients. Oncologists frequently use them in combination therapy either with radiotherapy or immunotherapy to treat patients showing resistance to first-line drug therapy. Immunotherapy is set to register impressive growth in the near future on account of its promising product pipeline which will be commercially available during the forecast period.

Get a sample copy for more information

"Rising prevalence of blood cancer and affordable reimbursement scenario for the medicines employed in its treatment together drive the market growth in North America"

North America with a market share of 34.6% is currently reigning the regional segment for blood and bone marrow cancer treatment market. The chief contributing factor for its market dominance is rising prevalence of blood cancer. According to the Leukemia and Lymphoma Society (CDC) facts and figures approximately after every 3 minutes 1 person in the U.S. is diagnosed with blood cancer. In 2019, in the United States, approximately 176,200 people are diagnosed with either leukemia, myeloma or lymphoma. Affordable reimbursement scenario for the medicines employed in its treatment is another important factor that contributes towards its regional market growth. Europe holds a share of 30.8% primarily due to the supportive regulatory framework provided by the European Medical Agency for the development and sale of medication for the treatment of blood cancer. Asia Pacific represents 18.4% market share on account of rising public health awareness related to blood cancer & its treatment and developing healthcare infrastructure.

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation comprises of by indication, therapy, and geography. 

Pharmaceutical companies spearheading the blood and bone marrow cancer treatment market are Bristol Myers Squibb & Company, AstraZeneca, Plc., Eli Lilly & Company, Johnson and Johnson Company, F.Hoffman La-Roche Ltd., Celgene, Inc.,  Merck & Co., Inc., Novartis AG, Varian Medical Systems, Inc. and Pfizer, Inc.

Key questions answered in this report

• Which pharmaceutical companies are providing medications for the treatment of blood and bone marrow cancer?
• What are the drivers' opportunities and restraints studied in the blood and bone marrow cancer treatment market?
• What is the prevalence rate of different types of blood cancer?
• What are the factors responsible for the large market share of chemotherapy?
• What will be the market performance of Asia Pacific, Middle East and Africa and Latin America during the forecast period?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global BBMCT Market Portraiture
2.2. Global BBMCT Market, by Indication, 2018 (US$ Bn)
2.3. Global BBMCT Market, by Therapy, 2018 (US$ Bn)
2.4. Global BBMCT Market, by Geography, 2018 (US$ Bn)

Chapter 3. Blood and Bone Marrow Cancer Treatment (BBMCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global BBMCT Market, by Key Players, 2018

Chapter 4. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Indication
4.1. Overview
4.2. Multiple Myeloma
4.3. Leukemia
4.4. Lymphoma
4.5. Others

Chapter 5. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Therapy
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Stem Cell Transplant
5.4. Radiotherapy
5.5. Pipeline Analysis
5.5.1. Phase III Drug
5.5.1.1. Eltrombopag
5.5.1.2. Avatrombopag
5.5.1.3. Hetrombopag
5.5.1.4. Omidubicel
5.5.1.5. Fedratinib
5.5.1.6. ATIR101
5.5.1.7. Pegylated Proline Interferon Alpha-2b
5.5.2. Tabular Representation of Phase II and I Pipeline Drugs

Chapter 6. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Geography
6.1. Overview
6.2. North America BBMCT Market Analysis, 2017– 2027
6.2.1. North America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America BBMCT Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe BBMCT Market Analysis, 2017 – 2027
6.3.1. Europe BBMCT Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific BBMCT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific BBMCT Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America BBMCT Market Analysis, 2017 – 2027
6.5.1. Latin America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa BBMCT Market Analysis, 2017 – 2027
6.6.1. MEA BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Celgene, Inc.
7.3. Bristol Myers Squibb & Company
7.4. Eli Lilly & Company
7.5. Johnson & Johnson Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis AG
7.9. Pfizer, Inc.
7.10. Varian Medical Systems, Inc.

* Here we are using BBMCT as a short form of Blood and Bone Marrow Cancer Treatment

FIG. 1 Blood and Bone Marrow Cancer Treatment (BBMCT) Market: Research Methodology
FIG. 2 BBMCT: Market Segmentation
FIG. 3 Global BBMCT Market, by Indication, 2018 (US$ Bn)
FIG. 4 Global BBMCT Market, by Therapy, 2018 (US$ Bn)
FIG. 5 Global BBMCT Market, by Geography, 2018 (US$ Bn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global BBMCT Market, by Key Players, 2018
FIG. 8 Global Multiple Myeloma Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 9 Global Leukemia Market for BBMCT, 2017– 2027 (US$ Bn)
FIG. 10 Global Lymphoma Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 11 Global Other Indication Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 12 Global Chemotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 13 Global Immunotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 14 Global Stem Cell Transplant Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 15 Global Radiotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 16 U.S. BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 17 Canada BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 18 U.K. BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 19 Germany BBMCT Market, 2017– 2027 (US$ Bn)
FIG. 20 Rest of Europe BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 21 China BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 22 Japan BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 23 Rest of Asia Pacific BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 24 Brazil BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 25 Mexico BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 26 Rest of Latin America BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 27 GCC BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 28 Rest of MEA BBMCT Market, 2017 – 2027 (US$ Bn)

TABLE 1 Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market Portraiture
TABLE 2 Global BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 3 Global BBMCT Market , by Therapy, 2017 – 2027 (US$ Bn)
TABLE 4 Global BBMCT Market, by Geography, 2017 – 2027(US$ Bn)
TABLE 5 North America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 6 North America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 7 North America BBMCT Market, by Country, 2017 – 2027 (US$ Bn)
TABLE 8 Europe BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 9 Europe BBMCT Market, by Therapy, 2017 – 2027(US$ Bn)
TABLE 10 Europe BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 11 Asia Pacific BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 12 Asia Pacific BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 13 Asia Pacific BBMCT Market, by Country/Region, 2017– 2027 (US$ Bn)
TABLE 14 Latin America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 15 Latin America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 16 Latin America BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 17 Middle East and Africa BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 18 Middle East and Africa BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 19 Middle East and Africa BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Celgene, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Bristol Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Johnson and Johnson Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)